See more : Thejo Engineering Limited (THEJO.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Recursion Pharmaceuticals, Inc. (RXRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Recursion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Cartica Acquisition Corp (CITEW) Income Statement Analysis – Financial Results
- DTXS Silk Road Investment Holdings Company Limited (0620.HK) Income Statement Analysis – Financial Results
- NanoSphere Health Sciences Inc. (NSHSF) Income Statement Analysis – Financial Results
- Chugai Ro Co., Ltd. (1964.T) Income Statement Analysis – Financial Results
- Global Internet of People, Inc. (SDH) Income Statement Analysis – Financial Results
Recursion Pharmaceuticals, Inc. (RXRX)
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 44.58M | 39.68M | 10.00M | 3.41M | 1.71M |
| Cost of Revenue | 42.59M | 48.28M | 9.10M | 63.32M | 45.81M |
| Gross Profit | 1.99M | -8.59M | 896.00K | -59.91M | -44.10M |
| Gross Profit Ratio | 4.46% | -21.66% | 8.96% | -1,755.23% | -2,577.32% |
| Research & Development | 241.23M | 155.70M | 135.27M | 63.32M | 45.81M |
| General & Administrative | 110.82M | 81.60M | 57.68M | 25.26M | 18.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 110.82M | 81.60M | 57.68M | 25.26M | 18.95M |
| Other Expenses | 0.00 | -162.00K | -178.00K | -549.00K | -608.00K |
| Operating Expenses | 352.05M | 237.13M | 192.78M | 88.03M | 64.15M |
| Cost & Expenses | 394.64M | 285.41M | 192.78M | 88.03M | 64.15M |
| Interest Income | 19.12M | 6.25M | 73.00K | 336.00K | 1.74M |
| Interest Expense | 97.00K | 55.00K | 2.95M | 1.36M | 635.00K |
| Depreciation & Amortization | 24.40M | 19.49M | 9.10M | 4.44M | 3.54M |
| EBITDA | -299.57M | -227.67M | -174.42M | -81.70M | -58.34M |
| EBITDA Ratio | -672.05% | -619.26% | -1,827.75% | -2,353.38% | -3,401.52% |
| Operating Income | -350.06M | -245.73M | -182.78M | -84.62M | -62.44M |
| Operating Income Ratio | -785.33% | -619.26% | -1,827.75% | -2,479.20% | -3,649.39% |
| Total Other Income/Expenses | 17.93M | 6.25M | -3.70M | -2.39M | 562.00K |
| Income Before Tax | -332.13M | -239.48M | -186.48M | -87.01M | -61.88M |
| Income Before Tax Ratio | -745.10% | -603.50% | -1,864.79% | -2,549.25% | -3,616.54% |
| Income Tax Expense | -4.06M | -55.00K | -8.41M | 876.00K | 646.00K |
| Net Income | -328.07M | -239.42M | -178.07M | -87.88M | -62.53M |
| Net Income Ratio | -735.99% | -603.36% | -1,780.74% | -2,574.92% | -3,654.30% |
| EPS | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| EPS Diluted | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Weighted Avg Shares Out | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
| Weighted Avg Shares Out (Dil) | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
3 Millionaire-Maker Biotech Stocks
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
Where Will Recursion Pharmaceuticals Be in 5 Years?
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround
Source: https://incomestatements.info
Category: Stock Reports